Header Logo

Connection

MEGHANA TRIVEDI to Estradiol

Back to Details
This is a "connection" page, showing publications MEGHANA TRIVEDI has written about Estradiol.
MEGHANA TRIVEDI
Connection Strength
0.330
Estradiol
  1. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
    View in: PubMed
    Score: 0.162
  2. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.108
  3. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
    View in: PubMed
    Score: 0.033
  4. Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2016 06; 157(2):203-210.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.